Patients with psoriatic arthritis who meet clinical criteria for minimal disease activity also tend to report good disease ...

The most recent AAD/National Psoriasis Foundation (NPF) clinical guidelines, published from 2019 to 2021, consist of six sections and more than 200 journal pages.

A new analysis highlights the effectiveness of risankizumab in patients with moderate plaque psoriasis and those newly classified as systemic therapy eligible under International Psoriasis Council ...

For patients with psoriasis and Type 2 diabetes, the risk of developing chronic kidney disease (CKD) continued to rise ...

AD and psoriasis were once thought to be opposites in terms of immune response, with AD linked to a Th2-dominant pathway and ...

A new Delphi consensus led by the National Psoriasis Foundation proposes a standardized definition of on-treatment remission ...

Skin diseases contribute significantly to morbidity worldwide, yet their burden in North Africa and the Middle East (NAME) remains poorly understood. This study aims to assess the burden of skin ...

Tumor necrosis factor (TNF) inhibitor therapy was effective in reducing the likelihood that psoriasis would progress to psoriatic arthritis (PsA), a retrospective study indicated. Among ...